About the Immunology Program
Program Leader: Yoji Shimizu, Ph.D.
The Immunology Program has 21 members from departments in the University of Minnesota Medical School, the College of Veterinary Medicine, and the College of Science and Engineering.
The scientific goal of the Immunology Program is to define the basic mechanisms that control adaptive immunity in order to develop immunotherapies that overcome the significant barriers associated with generating a durable immune response against tumor-associated antigens.
- Mechanisms of lymphocyte tolerance
- Lymphocyte activation and signal transduction
- Mechanisms of lymphocyte development
- Tumor immunology and immunotherapy
The Immunology Program meetings are held concurrent with meetings of the Center for Immunology.
Paul Bohjanen, M.D., Ph.D.
Role of mRNA decay in regulating T cell activation and function
Michael Farrar, Ph.D.
How cytokines and cytokine-dependent signal transduction pathways control regulatory T cell development and B cell leukemia
Brian Fife, Ph.D.
The PD-1 negative regulatory pathway in T cells and its role in controlling autoimmunity and preventing transplant rejection
Tanya Freedman, Ph.D.
How inflammation modulates macrophage responsiveness, including in the inflammatory tumor microenvironment, especially in breast cancer; the regulation of proto-oncogenic signaling proteins like the Src family kinases
Thomas Griffith, Ph.D.
The immunotherapeutic potential of TRAIL in preclinical models of advanced renal cell carcinoma and breast cancer
Kris Hogquist, Ph.D.
Molecular mechanisms of T cell development in the thymus; analysis of transgenic and gene-deficient mice, gene expression profiling, and RNAi "knock-down" analysis;immune response to the Epstein Barr Virus - a chronic viral infection associated with cancer and autoimmunity in humans
Stephen Jameson, Ph.D.
Mechanisms that regulate the development and maintenance of T cells in the body; T cell homeostasis in response to lymphopenia which offers an opportunity to enhance the function of residual T cells in lymphodepleted individuals, including cancer patients receiving radio- or chemotherapy
Marc Jenkins, Ph.D.
Investigation of CD4+ helper T and B cell activation in vivo by directly tracking antigen-specific cells, with the goal of achieving a basic understanding of lymphocyte signal transduction, proliferation, and differentiation so that these processes can be manipulated to improve vaccines and prevent autoimmunity
Ryan A. Langlois, Ph.D.
The interplay between innate and adaptive immune responses in the lung; mechanisms that drive immunopathology, cell death/survival and healing within the lung
Walter Low, Ph.D.
Development of immunotherapeutic approaches for the treatment of brain tumors
David Masopust, Ph.D.
Resident memory T cells, cytotoxic T cell migration and function within tissues, and CD8 T cell vaccines
Matthew Mescher, Ph.D.
Investigation of the basic mechanisms involved in CD8 activation and tolerance induction and their application to murine models of tumor immunotherapy. These basic research findings have been translated to the clinic with clinical testing of large multivalent immunogen therapy.
Jeffrey Miller, M.D.
How undifferentiated stem cells develop into functioning NK cell lymphocytes and the manipulation of NK cells to treat or prevent cancer relapse; targeted immunotherapy to treat human cancer
Christopher Moertel, M.D.
Clinical interests include pediatriac neuro-oncology; rare pediatric tumors; neurofibromatosis-associated neoplasia; and the therapy of children with brain and spinal cord tumors.
Daniel Mueller, M.D.
Biological and biochemical nature of immune self-tolerance and application to the treatment of autoimmune disease, allograft rejection, and immunotherapy of cancer
Christopher Pennell, Ph.D.
Enhancing the efficacy of DNA-based vaccines for cancer therapy
Erik Peterson, M.D.
The role of adaptor proteins in T cell development, regulation of T cell-dependent autoimmunity, and immune cell transduction
Liz Pluhar, D.V.M., Ph.D.
Gene therapy for glioblastoma multiforme (GBM) and developing dogs with spontaneous glioma as an exceptional large animal model for human GBM and mengingiomas
Daniel Saltzman, M.D., Ph.D.
Development of an attenuated strain of Salmonella typhimurium as an anti-cancer therapy capable of local delivery of immunostimulatory cytokines
Yoji Shimizu, Ph.D.
Intracellular signal transduction events that regulate adhesion interactions critical for effective antigen-specific immune responses and cell trafficking
Vaiva Vezys, Ph.D.
Investigation of how T cell tolerance to self-antigens, tumor antigens, and proteins from chronic infections is induced and maintained; development of methods for reversing established tolerance to these types of proteins and their translation to the clinic